18F-FDG PET/TC in TIR3A E TIR3B

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Feb 11, 2025

Keywords

ClinConnect Summary

This is an observational study from Bologna, Italy, looking at whether the standard PET/CT scan using a radioactive sugar tracer (18F-FDG) can help tell which thyroid nodules with unclear cytology are cancer. The researchers will compare what the PET/CT shows with the final tissue diagnosis from surgery to see how accurate the scan is. They’ll also explore whether combining PET/CT results with ultrasound, genetic testing, or other image analysis ideas could better predict cancer and help doctors decide who should have surgery versus who can be watched safely.

If you’re eligible, you’d be an adult (18+) with a thyroid nodule whose needle biopsy results are undetermined (TIR3A or TIR3B) and you’re planned for surgery or are being considered for surgery. About 216 people are expected to join at the Bologna center between 2022 and 2027. You may have already had a PET/CT at this center within the last 4 months of your biopsy, in which case that imaging can be used without repeating the scan. The study is purely observational—no new treatment is given—so the main extra step is the PET/CT scan and a careful review of the images by two specialists. As with any PET/CT, the usual scan-related radiation exposure applies. If this work matters to you, discuss with your doctor how it might relate to your care.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with undetermined cytology (TIR3B and TIR3A candidates for surgery) and 18F-FDG PET/CT;
• • Obtaining informed consent for data collection and processing.
• • Patient aged 18 years
• Exclusion Criteria:
• • - Pregnant/breastfeeding women